-
Entering the post-medical reform revision stage, pharmaceutical companies need to strengthen innovation and actively deploy overseas
Time of Update: 2022-11-11
In addition, the marketing applications for two new indications of drug H for the first-line treatment of small cell lung cancer and esophageal squamous cell carcinoma were successively accepted by the NMPA in April and August this year.
-
Get a new indication
Time of Update: 2022-01-22
As a new broad-spectrum triazole antifungal drug, Kangxinbo has successively been approved for two indications of invasive mucormycosis and invasive aspergillosis in adults, which will help the whole treatment of clinical invasive mycosis .
-
A number of major medical provinces officially began to implement the standard for traditional Chinese medicine formula particles
Time of Update: 2021-11-14
For example, since November 1, the Shaanxi Provincial Food and Drug Administration issued the "Shaanxi Provincial Traditional Chinese Medicine Formula Granule Standard" which has been formally implemented .
-
Merck's MET inhibitor Tepmetko is approved by the UK MHRA for the treatment of NSCLC patients
Time of Update: 2021-11-05
CompilationFan DongdongA few days ago, the British Medicines and Healthcare Products Regulatory Agency (MHRA) announced the conditional approval of Merck's MET inhibitor Teppetko (tepotinib) for the treatment of certain non-small cell lung cancer (NSCLC) patients .
-
Do "diabetics" need to "quit smoking
Time of Update: 2021-06-05
Although studies have shown that smoking cessation can lead to weight gain and blood sugar increase in type 2 diabetes (T2DM) patients in the short term, this effect will gradually weaken over time and will disappear after 3 to 5 years.
-
Yuandong Bio-Caffeine Citrate Injection Consistency Evaluation Supplementary Application Approved
Time of Update: 2021-04-29
On February 25, Chengdu Yuandong Biotech announced that the company's supplementary application for consistency evaluation of caffeine citrate injection was approved by the State Food and Drug Administration, passed the consistency evaluation, and agreed to change the prescription and production process.
-
Refused to Depression Scientists Analyze the Structure of "Happy Neurotransmitter" Receptor
Time of Update: 2021-03-26
On March 25th, Beijing time, "Nature" published a new research result of Chinese scientists, which reported for the first time in the world the five near-atomic resolution structures of serotonin receptors, an important target for depression.
-
Invest another $2.5 billion! Yang Sen is going to play the next big game in China
Time of Update: 2021-02-28
This investment was completed by Xi'an Yangsen, a Chinese pharmaceutical unit owned by Johnson and Johnson, to build a new supply chain production base in Xi'an for US$397 million (RMB2.55 billion) and is scheduled to start production in the second half of 2019 as an important physical preparation production center serving China and the Asia-Pacific region as a whole.
-
Fda approves Benlysta intravenous infusions for children with systemic lupus erythematosus
Time of Update: 2021-02-16
clinical trial looked at the efficacy of belimumab, which evaluated the efficacy, safety and pharmacodynamics of 93 active SLE children aged 5-17 years with standard therapy and placebo plus standard therapy.
The drug's safety and pharmacodynamic characteristics in child patients are consistent with among adult SLE patients.
-
Lilly Alzheimer's Drug Phase 2 clinically obtained positive data
Time of Update: 2021-01-31
it was terminated because there was no improvement in mild cognitive impairment caused by Alzheimer's disease and mild Alzheimer's disease in two Phase III clinical studies, and it was likely that it would be difficult to reach the end of the main efficacy, and then because of clinical results New findings with positive data have re-launched the listing application, and in August 2020, the FDA accepted and granted priority review of Alzheimer's disease's biopharmaceutical license for the new drug Aducanumab.
-
Hesco Class 1 innovative drug FTP-198 tablets were declared clinically accepted
Time of Update: 2020-11-07
IPF is a chronic, aggressive fibrosis lung disease with unknown epathy, which can cause peripheral pulmonary fibrosis remodeling, leading to respiratory failure, the incidence of which increases with age, and is common in people aged 60 to 70 years, and is the most common idynogenic interstitity pneumonia.
-
14 batches of drugs are not qualified 7 batches of hot lamb
Time of Update: 2020-09-30
Unqualified varieties are Chinese medicine drink tablets: Shan Tzu mushrooms, Wu Zhuyu, masturbation sheep (4 batches), Sichuan Wu, burning sheep squid (7 batches). non-conforming testing items: char
-
Industry: The third round of collection short-term will not bring a greater impact on the overall pharmaceutical sector
Time of Update: 2020-08-06
, in addition, with the normalization of collection, some of the original market share is not high once the winning bid, the relevant enterprises or have the opportunity to overtake the bend, to obtain a higher market share, to help the company to improve revenue levels.
-
Axa Pharmaceuticals has been awarded the second orphan drug title by the FDA: Bcl-2 inhibitor APG-2575 for the treatment of Fahrenheit polycypproteinemia
Time of Update: 2020-07-27
as !---- centage Pharma has announced that its new Bcl-2 inhibitor, APG-2575, is treating Fahrenheit polycylobinemia (WM), and has been awarded the orphan drug (ODD) by the U.S Food and Drug Administr
-
Zhejiang Jingxin Pharmaceuticals received CFDA approval issued by the heavy lig litadine kabaratin capsule drug registration approval
Time of Update: 2020-06-11
yesterday, Zhejiang Jing new drug (limited shares of the company (issued a notice that the company has received the State Food and Drug Administration approved the issuance of heavy lignin kabar
